PTO/SB/25 (05-03)

Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING **REJECTION OVER A PENDING SECOND APPLICATION**

Docket Number (Optional) 8325-0002.01

n re Application of: G.N. Cox III et al.

09/897,844 Application No.:

July 2, 2001

For Regulation of endogenous gene expression in cells using zinc finger proteins

The owner\*,  $\underline{\mathtt{BioSciences}}$ , of  $\underline{100}$  percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number  $\frac{09/706,243}{\text{filed on } 11/03/2000}$ , of any patent on the pending second application. The owner hereby agrees that any patent so

granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is an attorney or agent of record.

Signature

06/18/2003 ENGUYEN 00000117 09897844

01 FC:1814

110.00 OP

Typed or printed name

Sean Brennan

(510) 970-6000 ext. 252

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## SUBJECT: L JISION ON TERMINAL DISCLAIMERS IN DRMAL FORM

DATE: 8/6/03	APPL. S.N.: 09/897844
TO EXAMINER:	ART UNIT:
	LAWENCE MAILROOM DATE 7-17-0=
AFTER FINAL YES NO NUMBER OF T.D(S). FILED  INSTRUCTIONS: I have reviewed the submitted T.D. with the results as set forth below. If you agree, please use the approplate form paragraphs identified by this informal memo in your next office action to notify applicant about the T.D. If you disagree with my analysis or have questions at all about the acceptability of the T.D., please see me or our Special Program Examiner. THIS MEMO IS AN INFORMAL, INTERNAL MEMO ONLY. IT MUST NOT BE MAILED TO APPLICANT, NOR SHOULD A COPY BE IN LEFT IN FILE.	
The T.D. is PROPER and has been recorded.	See 14.23).
[ ] The T.D. is NOT PROPER and has not been a	ccepted for the reason(s) checked below. (See 14.24).
[ ] The recording fee of \$has not been to a deposit account. (See 14.26.07)	submitted nor is there any pre authorization in the application file to charge
[ ] Application Examiner has not processed T.D. fee. (See fee authorization).	
[ ] The T.D. does not satisfy nule 321(b)(3) in that (and/or the extent of the interest of the business entitle.26.01).	t the person who has signed the T.D. has no stated his/her interest by represented by the signature) in the application/patent. (See 14.26 and
[ ] The T.D. lacks the enforceable only during the c Rule 321(c). (See 14.27, 14.27, 01).	common owership clause needed to overcome a double patenting rejection,
[ ] It is directed to a particular claims(s), which is neterm of the entire patent to be granted. MPEP 1490	of acceptable since "the disclaimer must be of a terminal portion of the . (See 14.26, 14.26.02).
[ ] The person who signed the terminal disclaimer:     [ ] has failed to state his/her capacity to si     [ ] is not recognized as an officer of the as	gn for the business entity, (See 14.28). ssignee, (See 14.29 and possibly 14.29.01),
and fighte specified as to where such evidence is rec	the original inventor(s) to assignee has been submitted, nor is the reel corded in the office. 37 CFR 3.73(b). (See 1140 O.G. 72). <u>NOTE</u> : This additional in the T.D. or in a seperate paper submitted by
[ ] No "statement" specifying that the evidentiary do knowledge and belief the title is in the assignee seeki	cuments have been reviewed and that, to the best of the assignee's ng to take action. 37 CFR 3.73(b). (See 114d O.G. 72) (See 14.31).
[ ] The T.D. is not signed. (See 14.26, 14.26.3). or	14.26.03 if TD is not signed by all the owners.
[ ] Attorney not of record in oath/decl. or a seperate	paper filed appointing a new or associate attorney. (See 14.29.01).
[ ] The serial number of the application (or the number missing or incorrect. (See 14.32).	er of the patent) which forms the basis for the double patenting is
[ ] The serial number of this application (or the number incorrect. (See 14.26, 14.26.04 or 14.26.05).	per of the patent in reexam or reissue case(s, weing disclaimed is missing
[ ] The period disclaimed is incorrect or not specified	f. (See 14.27, 14.27.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)
[ ] Other:	
I. I. Currentles to a second	
[ ] Suggestion to request refund of \$ (S	·
MAY BE FAXED IN TO THE GROUP	NDITION FOR ALLOWANCE ANY OF THE ABOVE INFORMALTIES
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:	
<ul> <li>[ ] Sample of a TD over a pending application and assignee Certificate (See 14.37).</li> <li>[ ] Sample of a TD over a prior patent and assignee Certificate (See 14.38).</li> <li>[ ] Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39)</li> </ul>	